Dextropropoxyphene-paracetamol combinations are widely used as analgesics. At therapeutic doses, adverse reactions are uncommon but dependence is well recognized'. Haemolysis has been reported with propoxyphene in situations of abuse2 or in individuals with an innate susceptibility for haemolysis3,4.
Dextropropoxyphene-paracetamol combinations are widely used as analgesics. At therapeutic doses, adverse reactions are uncommon but dependence is well recognized'. Haemolysis has been reported with propoxyphene in situations of abuse2 or in individuals with an innate susceptibility for haemolysis3,4.
Steroid-responsive haemolysis has not been reported previously with either dextrbpropoxyphene or paracetamol, either singly or in combination. A patient with a 12 year history of haemolysis is reported.
Case report A 71-year-old woman with a 6 month history of tiredness presented in 1974. She had been previously well and was not known to be on any drug therapy. A macrocytic anaemia was discovered (haemoglobin 9.1 gIdl, mean corpuscular volume 129 fl, white cell count 4.5x 10/1, platelets 350x iOn/i, erythrocyte sedimentation rate 20 mm/h). Marrow examination revealed hyperactive erythropoiesis, absent stainable iron and no megaloblastic features. Vitamin B12, B12 absorption, ferTitin and folate were normal. Gastrointestinal investigations only revealed diverticulosis and a hiatus hernia. Reticulocytes were elevated at 20% and further indirect evidence of haemolysis was provided by elevated serum bilirubin and lactic dehydrogenase. Red cell survival, as measured by 51Chromium studies, was reduced to 4.5 days. Further investigations provided negative results to the following tests -Coombs (direct and indirect), Ham's, Schum's, viral serology, auteantibodies (antinuclear and rheumatoid factors, antimitochondrial and antismooth muscle antibodies), LE cells and skin immunofluorescence. Additional investigations with a normal result include serum lipids, vitamins, lead, trace elements; protein electrophoresis, red cell osmotic fragility, incubation fragility, glucose-6phosphate dehydrogenase test, liver and spleen isotope scan, chest X-ray, electrocardiogram, intravenous urography and routine bacteriological screening. Erthr coproporphyrin and protoprophyrin were both elevated.
A trial of prednisolone 30 mg/day was undertaken. Her haemoglobin rose dramatically from 7.2 g/dl to 12.7 g/dl in a 2 month period. Attempted withdrawal of steroids as an outpatient was unsuccesful as haemolysis recurred.
Prolonged withdrawal was achieved as an inpatient, with a relapse following discharge. Maintenance prednisolone (10 mg/day) controlled her condition over the next 5 years.
In 1979, she was lost to follow-up, but was re-admitted in January 1987 with significant anaemia. SWe was not on steroid therapy on admission and her recognized drug therapy of Gaviscon, vitamin B,2, folic acid and ferrous sulphate was not thought to have aetiological significance. Conversely, her further history of chronic, periodic and occasionally excessive, intake of Co-proxamol/Distalgesic tablets (dextropropoxyphene hydrochloride 32.5 mg, paracetamol 325 mg) was considered relevant. The original indication for the prescription of Co-proxamol was nonspecific back pain in 1973. Thereafter, she used the drug as a panacea. Her daily intake of Co-proxamol varied between 4 and 8 tablets, with an occasional maimum of 12 tablets. Withdrawal of these tablets, with reintroduction of prednisolone, cured her anaemia. Steroids were successfully withdrawn as an outpatient. Rechallenge with either the combination tablet, or the component substances, was not considered ethical. As her use of Co-proxamol had laterally been irrational, no alternative analgesic nor anti-inflammatory agent was prescribed.
Discussion
Drug* are a relatively common cause of acquired haemolytic anaemia. Some, for example, dapsone, cause a degree of haemolysis in virtually all who use it; others, for example, phenacetin, only cause haemolysis when ingested in high doses. Others, for example, nomifensine, may induce idiosyncratic haemolysis. Mechanisms include direct red cell toxicity, red cell membrane damage and either immune or autoimmune haemolysis. In most cases, the offending substance is easily recognizable and its withdrawal removes the stimulus for haemolysis. Prolongation of the course of haemolysis is often due to failure of recognition ofthe cause, a task complicated by an atypical form of haemolysis triggered by a drug previously thought to be innocent.
However, Distalgesic/Co-proxamol (Dista Products Limited) is liable to have a low propensity for causing haemolysis, as evidenced by its wide usage and the lack of previous reports ofhaemolysis. The underlyingm anism is unclear, althoukh the steroid resposiveness implies that immune or autoimmune factors may be contributory. This was not confirmed, or refuted, by the above investigation.
In summary, undeclared usage of a common analgesic resulted in i steriod-responsive haemolytic anaemia in an elderly woman. Her clinical course was prolonged due to the previnus lack of recognition of haemolysis as an adverse reaction of dextropropoxyphene combinations.
